论文部分内容阅读
对98例丙肝患者进行了HCV基因分型检测,结果表明Ⅱ、Ⅲ、Ⅱ/Ⅲ混合和未分化型依次为70、11、15和2例。98例随机分为二组治疗,干扰素组50例、对照组48例,3个月疗程结束时干扰素组之肝功能复常率和HCV RNA转阴率皆显著优于对照组(P<0.05)。Ⅱ、Ⅲ、Ⅱ/Ⅲ混合以及未分型者之ALT复常率和HCV RNA转阴率依次为72.7％、100.0％、75.0％和100.0％以及54.3％、100.0％、55.6％和100.0％。以Ⅱ型疗效差。此外,同为Ⅱ型患者急肝组HCVRNA转阴率仍达88.2％,慢肝14例中仅4例阴转,占28.6％,两者差异显著(P<0.005),提示早期干扰素治疗有助于病毒清除和肝功复常。
HCV genotypes were detected in 98 hepatitis C patients. The results showed that the mixed, undifferentiated forms of Ⅱ, Ⅲ, Ⅱ / Ⅲ were 70, 11, 15 and 2 cases. 98 cases were randomly divided into two groups: interferon group (n = 50) and control group (n = 48). The normalization rate of hepatic function and HCV RNA negative rate in the interferon group were significantly better than those in the control group at the end of 3 months (P < 0.05). The ALT normalization rate and HCV RNA negative rate were 72.7%, 100.0%, 75.0% and 100.0% and 54.3%, 100.0%, 55.6% and 100.0% respectively in the mixed and undifferentiated groups Ⅱ, Ⅲ and Ⅱ / Ⅲ. To type Ⅱ poor efficacy. In addition, the same type Ⅱ patients with acute hepatic HCV RNA still rate was 88.2%, slow liver in 14 cases, only 4 cases of negative conversion, accounting for 28.6%, a significant difference between the two (P <0.005), suggesting that early interferon therapy To help clear the virus and liver function.